humanitarian
Archived signal
Human medicines European public assessment report (EPAR): Soliris, eculizumab, Date of authorisation: 20/06/2007, Revision: 42, Status: Authorised
Human medicines European public assessment report (EPAR): Oncaspar, pegaspargase, Date of authorisation: 14/01/2016, Revision: 21, Status: Authorised
Reported by EMA What Is New
Read the complete report at EMA What Is New ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
8 reports · 2 sources
EMA What Is NewHuman medicines European public assessment report (EPAR): Soliris, eculizumab, Date of authorisation: 20/06/2007, Revision: 42, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Soliris, eculizumab, Date of authorisation: 20/06/2007, Revision: 42, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Clopidogrel Viatris (previously Clopidogrel Taw Pharma), clopidogrel, Date of authorisation: 16/10/2009, Revision: 30, St…EMA What Is NewHuman medicines European public assessment report (EPAR): Clopidogrel Viatris (previously Clopidogrel Taw Pharma), clopidogrel, Date of authorisation: 16/10/2009, Revision: 30, St…EMA What Is NewHuman medicines European public assessment report (EPAR): Pirfenidone Viatris, pirfenidone, Date of authorisation: 10/01/2023, Revision: 5, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Pirfenidone Viatris, pirfenidone, Date of authorisation: 10/01/2023, Revision: 5, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Oncaspar, pegaspargase, Date of authorisation: 14/01/2016, Revision: 21, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Oncaspar, pegaspargase, Date of authorisation: 14/01/2016, Revision: 21, Status: Authorised4 recorded states
Signal first indexedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Headline updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources